Determine MTD and to Evaluate PK, Safety/Tolerability and Efficacy Profiles of Antroquinonol (Hocena RM) in NSCLC Patients Refractory to Conventional Treatment Modalities

Trial Profile

Determine MTD and to Evaluate PK, Safety/Tolerability and Efficacy Profiles of Antroquinonol (Hocena RM) in NSCLC Patients Refractory to Conventional Treatment Modalities

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Antroquinonol (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Golden Biotechnology Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Mar 2013 Planned end date changed from 1 Mar 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top